Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT02091063 2024-08-06

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
23 enrolled 6 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02661815 2019-11-08

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
6 enrolled 8 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡